Axcella Health Inc. Stock News

Tenet Healthcare's (THC) first-quarter 2022 results are likely to reflect an improvement in adjusted admissions and outpatient admissions.

Moderna's (MRNA) two vaccine candidates, mRNA-1020 and mRNA-1030, target both hemagglutinin and neuraminidase protein for providing better protection against the influenza virus. The company initiates

Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.

Rhythm Pharmaceuticals (RYTM) modifies the design of its two genetic obesity disorder studies to focus on rare patients, thus reducing the targeted population size. RYTM expects to save costs in the p

Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. It completes the rolling submission of an NDA for the same. Stock rises.

Here is how Avanos Medical (AVNS) and Axcella Health Inc. (AXLA) have performed compared to their sector so far this year.

Axcella Health Inc. (AXLA) CEO Bill Hinshaw on Q4 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endoge

US stocks closed higher with the Nasdaq Composite jumping over 2% on Friday. Investors, meanwhile, focused on some notable insider trades When insiders purchase or sell shares, it indicates their conf

The US Federal Reserve, on Wednesday, raised its target fed funds rate by 0.25%, its first interest rate hike since 2018. Investors, meanwhile, focused on some notable insider trades When insiders pur

The US Federal Reserve, on Wednesday, raised its target fed funds rate by 0.25%, its first interest rate hike since 2018. Investors, meanwhile, focused on some notable insider trades When insiders pur

With contract labor headwinds likely to phase out as 2022 progresses, Community Health Systems' (CYH) margins are set to improve significantly.

Anthem's (ANTM) Medicaid footprint is likely to grow on the back of the pending acquisition of Paramount Advantage's Ohio contracts, as service is expected to commence in July.

Axcella Therapeutics (Nasdaq: AXLA) announced that the FDA has granted a Fast Track Designation to AXA1125. These are the details.

Axcella Health Inc (AXLA) shares closed today at 1.1% above its 52 week low of $1.80, giving the company a market cap of $70M. The stock is currently down 12.9% year-to-date, down 68.0% over the past 12 months, and down 86.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 53.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 955.4% The company's stock price performance over the past 12 months lags the peer average by 622.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.